Taming the "Trojan Horse": Preclinical Safety Strategies and Off-Target Risk Mitigation for Solid Tumor ADCs
Antibody-Drug Conjugates (ADCs) have revolutionized oncology, earning their reputation as biological "Trojan horses."
Technology
